A highly sensitive turn‐off fluorescent probe based on 2D Eu(III)‐MOFs nanosheets for glutathione in vitro and living cells

Mengmeng Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Huili Li(East China Normal University), Song Hu(University of Science and Technology Beijing), Danyu Jiang(Chinese Academy of Sciences), Guohong Zhou(Chinese Academy of Sciences), Hairong Zeng(Shanghai University of Traditional Chinese Medicine), Yunpeng Liu(Shenyang Institute of Automation), Chao Xia(Sichuan Agricultural University)
Journal of the American Ceramic Society
October 31, 2022
10.1111/jace.18869
Cited by 4

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412